-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On June 4, 2021, Daiichi Sankyo announced that its research antibody conjugate (ADC) patritumab deruxtecan, targeting HER3, is in the treatment of non-small cell lung cancer (NSCLC) with drug-resistant EGFR mutations.
Patritumab deruxtecan is one of the three main DXd ADCs produced by Daiichi Sankyo.
The test results showed that among 57 enrolled patients who received patritumab deruxtecan (5.
▲Patritumab deruxtecan preliminary clinical trial research results (picture source: reference [1])
Lung cancer is one of the most common cancers and the leading cause of cancer deaths worldwide
Note: The original text has been deleted
Reference materials:
[1] Patritumab Deruxtecan Data at ASCO Demonstrates Tumor Response Across Multiple Resistance Mechanisms in Patients with Advanced EGFR-Mutated NSCLC.